M1FG
TVTX icon

Mach-1 Financial Group’s Travere Therapeutics TVTX Stock Holding History

Mach-1 Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,313
Closed -$301K – 396
2025
Q2 		$301K Buy
+20,313
New +$337K 0.09% 206

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Mach-1 Financial Group's TVTX Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 20,313 shares — an estimated $301K sold.

Mach-1 Financial Group first reported a position in TVTX in Q2 2025 and held it in 1 quarter. The position peaked at $301K in Q2 2025. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 20,313 Travere Therapeutics shares in Q3 2025, an estimated $301K.
  • Mach-1 Financial Group first reported a position in Travere Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Travere Therapeutics position peaked at $301K in Q2 2025.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.